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OBJECTIVE — Cystic ﬁbrosis–related diabetes (CFRD) without fasting hyperglycemia
(CFRD FH) is not associated with microvascular or macrovascular complications, leading to
controversy about the need for treatment. The Cystic Fibrosis Related Diabetes Therapy
(CFRDT) Trial sought to determine whether diabetes therapy improves BMI in these patients.
RESEARCH DESIGN AND METHODS — A three-arm multicenter randomized trial
compared 1 year of therapy with premeal insulin aspart, repaglinide, or oral placebo in subjects
with cystic ﬁbrosis who had abnormal glucose tolerance.
RESULTS — One hundred adult patients were enrolled. Eighty-one completed the study,
including61withCFRDFHand20withseverlyimpairedglucosetolerance(IGT).Duringthe
year before therapy, BMI declined in all groups. Among the group with CFRD FH, insulin-
treated patients lost 0.30  0.21 BMI units the year before therapy. After 1 year of insulin
therapy, this pattern reversed, and they gained 0.39  21 BMI units (P  0.02). No signiﬁcant
change in the rate of BMI decline was seen in placebo-treated patients (P  0.45). Repaglinide-
treated patients had an initial signiﬁcant BMI gain (0.53  0.19 BMI units, P  0.01), but this
effect was not sustained. After 6 months of therapy they lost weight so that by 12 months there
was no difference in the rate of BMI change during the study year compared with the year before
(P  0.33). Among patients with IGT, neither insulin nor repaglinide affected the rate of BMI
decline. No signiﬁcant differences were seen in the rate of lung function decline or the number
of hospitalizations in any group.
CONCLUSIONS — Insulin therapy safely reversed chronic weight loss in patients with
CFRD FH.
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A
pproximately 30,000 individuals
with cystic ﬁbrosis live in the U.S.
With steady advances in medical
care, average life expectancy is now 38
years. Diabetes due to insulin insufﬁ-
ciency is the most common comorbidity
in this population, occurring in 40–50%
of adult patients with cystic ﬁbrosis (1).
Approximately 15% have diabetes with
fasting hyperglycemia (CFRD FH) and
require insulin therapy to prevent classic
diabetes symptoms and microvascular
complications. The 25% of adult patients
with cystic ﬁbrosis who have diabetes
without fasting hyperglycemia (CFRD
FH) pose a greater clinical dilemma.
During a standard oral glucose tolerance
test (OGTT), they have normal fasting
glucose levels, but their 2-h glucose is
200 mg/dl (11.1 mmol/l). It has been
argued that patients with CFRD FH do
not require diabetes therapy because they
are asymptomatic, have relatively normal
glucoselevelswhenmeasuredathomeby
self-monitoring of blood glucose, and
have minimal A1C elevation (2). Unlike
the general diabetic population, they do
not appear to be at risk for microvascular
or macrovascular complications (3).
However, it has also been argued that al-
thoughthemetaboliccomplicationsofin-
termittent postprandial hyperglycemia
may not be severe in these patients, the
nutritional consequences of insulin deﬁ-
ciency may be life-threatening (4).
Survival of individuals with cystic ﬁ-
brosis is intimately connected to nutri-
tional status; underweight and protein
catabolism are associated with poor pul-
monary function and death. Insulin is a
potent anabolic hormone, and insulin-
insufﬁcient cystic ﬁbrosis patients have
increased protein and fat breakdown (4–
6). Pulmonary function decline is also
related to the severity of insulin insufﬁ-
ciency (7). Thus, insulin insufﬁciency
may increase morbidity and mortality by
contributing to loss of weight and lean
body mass. We hypothesized that insulin
therapy would reverse nutritional deteri-
oration in these patients.
The addition of an insulin regimen is
asigniﬁcanttreatmentburdenforpatients
whose lives involve complex and time-
consuming medical care, and prescrip-
tion of such a regimen requires clear
evidence of beneﬁt. The question of
whether CFRD FH patients should re-
ceive diabetes therapy was given the
highest research priority by a national
consensus conference on CFRD (2). The
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(CFRDT) Trial was undertaken to deter-
mine whether premeal therapy with ei-
ther rapid-acting insulin or the oral
insulin secretagogue repaglinide would
improve BMI in this population.
RESEARCH DESIGN AND
METHODS— Fourteen cystic ﬁbrosis
centersintheU.S.,Canada,andU.K.par-
ticipated. The University of Minnesota
was the Coordinating Center, and the
Data Management Center was located
at the University of Massachusetts
(Amherst, MA). Participating centers
routinely performed annual OGTT
screening. Fasting subjects were given
1.75 g/kg (maximum 75 g) of an oral glu-
cose solution, and glucose levels were
measured over 2 h. OGTTs were per-
formed during stable baseline health.
Patients with cystic ﬁbrosis who had
CFRD FH (fasting plasma glucose
126 mg/dl [7.0 mmol/l] and 2-h glu-
cose 200 mg/dl [11.1 mmol/l]) or se-
vere impaired glucose tolerance (IGT)
(glucose level 200 mg/dl [11.1 mmol/l]
during the OGTT and a 2-h glucose level
of 180–199 mg/dl [10.0–11.1 mmol/l])
were recruited. Additional eligibility cri-
teria included completion of linear
growth, stable weight within 5% during
the previous 3 months, and no evidence
of acute infection in the previous 2
months. Exclusion criteria included fast-
ing hyperglycemia in the previous year,
oral or intravenous glucocorticoid ther-
apy in the previous 6 months, liver
dysfunction, and pregnancy. Block ran-
domization, using a pseudo–random
number generator with stratiﬁcation by
center, was used to ensure a more even
distribution of treatments over time and
across sites in the study. One-third of pa-
tients per block were assigned to each
treatment arm. Institutional review board
approval was obtained at the Coordinat-
ing Center and at each center; informed
consent was obtained from all subjects.
Treatment protocol
Patients were randomly assigned to re-
ceive 0.5 unit insulin aspart/15 g dietary
carbohydrate, 2.0 mg repaglinide orally,
or oral placebo three times a day before
meals. The oral agents were double-
blinded; there was no injectable placebo
because of ethical concerns. Study coor-
dinators contacted patients weekly. If
subjects experienced hypoglycemia, ad-
ditionaleducationwasprovidedtoensure
sufﬁcient carbohydrate intake. If dietary
measures were insufﬁcient to prevent
postprandial hypoglycemia, the medica-
tion dose was reduced. Persistent post-
prandial hyperglycemia led to a dosage
increase. Subjects were followed for 1
year and were seen by the study team
quarterly. Insulin vials and pill bottles
were returned quarterly for medication
adherence monitoring.
Ongoing diabetes education was pro-
vided.Dietaryrecommendationswerethe
sameasforallpatientswithcysticﬁbrosis,
including consumption of a high-calorie
diet with three meals and at least three
snacksperdaywithnorestrictionontotal
daily carbohydrate intake. Patients were
taught carbohydrate counting and in-
structed to consume a minimum of 60 g
carbohydrate with each meal to reduce
the risk of hypoglycemia. Those receiving
rapid-acting insulin were taught to match
the insulin dose to the carbohydrate con-
tent of the meal at a dose of 0.5 unit/15 g
carbohydrate.
Patients with CFRD FH are at risk
for permanent progression to CFRD
FH. This was a planned stopping point
because it required patients to switch to
basal-bolusinsulintherapy.However,pa-
tients with cystic ﬁbrosis can develop
transient fasting hyperglycemia during
acute illness. Patients were withdrawn
from the study only if they developed
acute illness-associated fasting hypergly-
cemia that persisted for 1 month, at
which point a chronic change in their di-
abetes condition was considered to have
occurred.Inaddition,patientswerewith-
drawniftheyrequiredsystemicglucocor-
ticoidsfor1monthbecauseoftheeffect
of these drugs on BMI.
Study end point measurement
All patients were followed at accredited
cystic ﬁbrosis centers with standardized
procedures for quarterly measurement of
clinical outcomes including BMI and pul-
monary function. BMI was chosen as the
primary study end point because it is well
correlated with survival in cystic ﬁbrosis
(8–10). BMI and lung function parame-
tersmeasured12monthsbeforestudyen-
try were obtained from chart review.
During the study they were prospectively
measured quarterly. Additional measures
obtained at baseline and 12 months in-
cluded dual-energy X-ray absorptiometry
for body composition, the National Insti-
tutes of Health (NIH) prognostic score (a
measure of overall clinical health)
(11,12),avalidatedcysticﬁbrosisquality-
of-life (CFQOL) survey (13), 3-day di-
etary histories, A1C (measured centrally
at University of Minnesota), and fasting
and 90-min after main meal capillary glu-
cose levels obtained at home by self-
monitoring of blood glucose.
Data analysis
Summary statistics were constructed at
each measurement occasion with the use
ofmeans,SDs,medians,andinterquartile
ranges for continuous factors and fre-
quencies and percentages for categorical
factors. 
2 or Fisher’s exact tests were
used to evaluate association of treatment
arm and baseline OGTT status with pa-
tient baseline characteristics, study com-
pletion,andtreatmentadherenceforeach
categorical factor; ANOVA models were
used to evaluate differences for continu-
ous-scale factors. To assess treatment ef-
fects, a series of ANCOVA models for
change from baseline in BMI, forced vital
capacity (FVC), and forced expiratory
volume in time interval (FEV1) were
evaluated for each measurement occa-
sion, adjusting for patient baseline char-
acteristics, adherence, and prior-year
change. Initial models included all
subjects with data available at each mea-
surement occasion. Final models were
stratiﬁed by OGTT class (FH or IGT) at
baselineandincludedthe81patientswho
completed the full study year. Additional
models were used to evaluate the change
from baseline to 1 year in fat-free mass,
NIH score, CFQOL, and A1C.
RESULTS
Study enrollment, dropouts, and
adherence
One hundred patients were enrolled, 74
with CFRD FH and 26 with severe IGT.
Nineteen dropped out or were stopped
early; the study was completed by 77% of
subjects with IGT and 82% of subjects
with CFRD FH (P  0.57). There was
no difference by treatment group in the
percentage of patients dropping out/
stoppingearly(P0.87)(supplementary
Appendix B, available at http://care.
diabetesjournals.org/cgi/content/full/dc9-
0585/DC1).Amongallparticipants,eight
chosetoquit,includingﬁve(13%)receiv-
ing insulin and three (5%) receiving oral
therapy (P  0.25). Five patients were
stopped early because they developed
permanent fasting hyperglycemia, in-
cluding two (5%) receiving insulin, three
(10%) receiving placebo, and none re-
ceiving repaglinide (P  0.27). Six addi-
tional patients (one receiving insulin and
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the study for other medical reasons, in-
cluding chronic use of steroids (one re-
ceiving insulin and one receiving
repaglinide), pregnancy (one receiving
repaglinide), rash attributed by the pa-
tient to medication (placebo), and chronic
hospitalization, too ill to take medication
(two receiving repaglinide) (P  0.12 for
association of reason for discontinuation
with treatment). Reasons for dropout are
shown in supplementary Appendix C
(available in an online appendix).
Study drug adherence was similar
among the study arms. Compliance data
were available at 75% of study visits.
Patients were deemed compliant if they
used 90% of the expected drug; 25%
of those with adherence data were
deemed noncompliant. This result is sim-
ilar to the reported adherence to medica-
tionregimensinadultswithcysticﬁbrosis
(14). There was no difference in adher-
ence between those with CFRD FH and
IGT(P0.91)andnodifferencebytreat-
ment arm (P  0.91).
Baseline characteristics
There were no signiﬁcant differences in
baseline characteristics between patients
who completed the study and those who
stopped early, with the exception of
CFQOL. Those who stopped early had
lower scores for eating disturbance (P 
0.05) and social/marginalization scales
(P  0.05).
Baseline characteristics of the 81
study completers are presented in Table
1. Patients in the placebo group appeared
slightly healthier at baseline, with some-
what higher BMI and better pulmonary
function, but these did not achieve statis-
tical signiﬁcance. Age, baseline BMI, and
BMI change during the preceding year,
baseline lung function and change during
the preceding year, body composition,
and CFQOL did not differ between pa-
tients with CFRD FH and IGT. How-
ever, a greater proportion of those with
IGT were men (75 vs. 49%, P  0.04). As
expected, A1C was lower in the IGT
group (5.5  0.4 vs. 6.1  0.6%, P 
0.0002).
Treatment effect on body
composition
Change in BMI the year before study par-
ticipation was compared with change
during the study year (Table 2). The pre-
vious year, all groups showed a decline in
BMI with no signiﬁcant difference among
treatment groups in the loss (Fig. 1). In-
sulin-treated patients with CFRD FH
lostanaverageof0.300.21BMIunitin
the year before therapy ( 2.5 pounds in
women and 3 pounds in men). After 1
Table 1—Baseline characteristics of the 81 subjects who completed the CFRDT trial
CFRD FH IGT
Total
cohort Insulin Repaglinide Placebo
Total
cohort Insulin Repaglinide Placebo
n 61 23 22 16 20 7 4 9
n (% female) 31 (51)* 12 (52) 11 (50) 8 (50) 5 (25) 3 (43) 0 (0) 2 (22)
Age (years) 28  92 9  22 6  22 8  32 8  72 7  22 9  52 8  2
BMI (kg/m
2) 21.3  2.9 20.6  0.6 21.3  0.7 22.2  0.6 22.0  2.7 20.7  0.7 22.9  1.7 22.5  0.9
% Fat-free mass 79  97 9  28 0  27 7  28 0  88 1  37 9  58 0  3
FVC (% predicted) 90  22 87  49 0  69 4  48 8  17 79  78 2  10 98  4
FEV1 (% predicted) 70  25 63  57 1  67 8  56 9  21 61  76 1  13 78  6
NIH score 83  13 80  38 4  38 8  38 2  14 79  67 4  98 9  2
A1C (%) 6.1  0.6* 6.2  (0.1) 6.2  0.1 6.0  0.1 5.5  0.4 5.5  0.3 5.6  0.1 5.5  0.1
Data for the CFRD FH and IGT total cohorts are means  SD; data by treatment group as means  SEM. There were no signiﬁcant differences across treatment
groups for CFRD FH or IGT. *Total cohort CFRD FH vs. IGT, P  0.05.
Table 2—Comparison of the change in BMI and lung function the year before and after 1 year of study participation
CFRD FH IGT
Insulin Repaglinide Placebo Insulin Repaglinide Placebo
n 61 20
BMI
12 months to baseline (kg/m
2) 0.30  0.21 0.14  0.21 0.29  0.25 0.60  0.30 0.08  0.40 0.66  0.27
Baseline to 12 months (kg/m
2) 0.39  0.21 0.15  0.21 0.02  0.25 0.26  0.30 0.71  0.40 0.24  0.27
P value 0.02 0.33 0.45 0.43 0.28 0.02
FVC
12 months to baseline (% predicted) 5.8  2.0 5.5  2.1 4.3  2.5 2.0  4.2 3.4  5.6 2.8  3.7
Baseline to 12 months 0.5  2.0 2.1  2.1 1.1  2.5 10.3  4.2 3.1  5.6 5.1  3.7
P value 0.21 0.25 0.37 0.05 0.96 0.6
FEV1
12 months to baseline (% predicted) 5.7  2.2 6.5  2.2 0.5  2.7 0.6  5.6 2.5  7.4 2.8  4.9
Baseline to 12 months 1.8  2.2 1.3  2.2 3.0  2.7 12.1  5.6 4.9  7.4 11.5  4.9
P value 0.21 0.10 0.51 0.12 0.82 0.05
Data are means  SEM.
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ceived premeal rapid-acting insulin re-
versed this chronic downward clinical
course and gained 0.39  21 BMI unit
(P  0.02) (Fig. 1). Weight gain distribu-
tion was about 80% fat and 20% fat-free
mass. No signiﬁcant difference in the rate
of BMI loss relative to the prior year was
seen in placebo-treated CFRD FH pa-
tients (P  0.45). Patients who received
repaglinide had an initial signiﬁcant gain
of0.530.19BMIunitswithintheﬁrst6
monthsoftherapy(P0.01).Thiseffect,
however, was not sustained. After 6
monthstheylostweightsothatbytheend
of 12 months there was no difference in
the rate of BMI change during the study
year compared with the year before (P 
0.33). Adjustment for baseline BMI,
weight, or sex did not inﬂuence these
conclusions. Changes in body composi-
tion were not related to dietary intake;
therewasnosigniﬁcantdifferenceindaily
calorie consumption from baseline to 12
months in any treatment group and no
differences between the groups. The ab-
solute change in BMI during the study
year did not differ signiﬁcantly between
CFRD FH groups (P  0.36, insulin
vs. placebo; P  0.95, repaglinide vs.
placebo; and P  0.35, insulin vs.
repaglinide).
Among patients with IGT, neither
the insulin- nor the repaglinide-treated
groups showed a signiﬁcant difference in
the rate of BMI decline during the study
year compared with the previous year. A
signiﬁcant improvement was seen in the
placebo group (P  0.02). The absolute
change in BMI during the study year was
signiﬁcantlyworseforrepaglinide-treated
patients with IGT (P  0.34, insulin vs.
placebo; P  0.03, repaglinide vs. pla-
cebo; and P  0.18, insulin vs.
repaglinide).
Treatment effect on clinical status
A1C levels did not signiﬁcantly change in
any group. After 1 year of therapy there
was no difference in fasting glucose be-
tweentreatmentgroupsandnodifference
frombaseline.Postprandialglucose,how-
ever,wassomewhatlowerinthosereceiv-
ing insulin therapy, although this did not
achieve statistical signiﬁcance. For CFRD
FH patients, the 90-min postprandial
glucose was 116  4 mg/dl (6.4  0.2
mmol/l) in the insulin group, 138  12
mg/dl (7.7  0.7 mmol/l) in the placebo
group, and 131  7 mg/dl (7.3  0.4
mmol/l) in the repaglinide group (P 
0.06, insulin vs. placebo and P  0.81,
repaglinide vs. placebo). Among those
with IGT, the 90-min postprandial glu-
cose was 114  3 mg/dl (6.3  0.2
mmol/l) in the insulin group, 122  4
mg/dl (6.8  0.2 mmol/l) in the placebo
group, and 131  9 mg/dl (7.3  0.5
mmol/l) in the repaglinide group (P 
0.20, insulin vs. placebo; P  0.81, repa-
glinide vs. placebo; and P  0.03, insulin
vs. repaglinide).
Althoughthereappearedtobeatrend
toward less decline in FVC in all of the
CFRD FH study arms and less decline
in FEV1 in the insulin and repaglinide
arms, these changes were not statistically
signiﬁcant (Table 2). There were no dif-
ferences in the number of episodes of
acute illness during the study year by
treatment arm or OGTT class. NIH and
CFQOL scores did not differ between
groups at baseline or over the treatment
year in any group.
Adverse events
Noseriousadverseeventsrelatedtostudy
medication occurred. In the ﬁrst 3
months, signiﬁcantly more patients re-
ceiving active medication compared with
thosereceivingplaceboreportedmildhy-
poglycemic events (insulin 16%, repa-
glinide 23%, and placebo none, P 
0.04). In most cases these resolved with
patient education. After the ﬁrst 3
months, there were no signiﬁcant differ-
ences between groups in the frequency of
hypoglycemia, and there were some epi-
sodes of mild hypoglycemia reported by
patients receiving placebo. Of 30 subjects
receiving insulin who completed the
study,persistentpostprandialglucoseab-
normalities led to an increased dose in 4
patients (13%) and a decreased dose in 2
patients (7%). Of 26 subjects receiving
repaglinide who completed the study,
persistent postprandial glucose abnor-
malities led to an increased dose in 3 pa-
tients (12%) and a decreased dose in 4
patients (15%).
CONCLUSIONS — It has been hy-
pothesizedthatinsulininsufﬁciencycom-
promises health and survival in cystic
ﬁbrosis by producing a catabolic state
with associated weight loss and reduced
Figure1—BMI12monthsbeforeand6and12monthsaftertreatmentwithinsulin(red),placebo
(blue), or repaglinide (black) in 61 subjects with CFRD FH (A) and 20 subjects with IGT (B).
Data are means  SEM. P values are for study year (0–12 months) compared with previous year
(12 to 0 months) within each group.
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suggested that weight and/or pulmonary
function may improve after institution of
insulin therapy, but none of these studies
were randomized controlled trials and
mosthadmixedpopulationsofCFRDpa-
tients with and without fasting hypergly-
cemia (15–20). In the current placebo-
controlled multicenter trial, insulin
replacement therapy signiﬁcantly re-
versed the trajectory of chronic weight
loss in CFRD FH patients.
No signiﬁcant changes were seen in
the annual rate of decline in FEV1 or FVC
orthenumberofacuteillnesses,andthere
were no changes from baseline in NIH
scores. These ﬁndings are not surprising
given that an earlier study required 4
years of observation before signiﬁcant
trends in lung function could be docu-
mented between subjects with normal,
impaired, and diabetic glucose tolerance
(7). Patients with cystic ﬁbrosis die of
chronic inﬂammatory lung disease, and
ultimately lung function is the most im-
portant end point. However, body weight
is strongly related to cystic ﬁbrosis lung
function and survival (8–10).
In the current study, insulin-treated
patientsstoppedlosingweightandgained
both fat and lean body mass. This result
seemed to be mediated primarily via the
anabolic rather than the glucose homeo-
static effect of insulin because it was ac-
complished without a signiﬁcant change
in A1C or blood glucose levels. Although
total caloric intake did not differ between
groups and all patients received the same
education with regard to carbohydrate
counting,wecannotexcludethepossibil-
ity that patients receiving insulin therapy
were more attentive to carbohydrate in-
take because they were matching it to in-
sulin dose and because patients receiving
insulin were not blinded.
Repaglinide had a transient effect on
weightgaininCFRDFHpatients.Itwas
chosen for this study because sulfonyl-
ureas had previously been anecdotally as-
sociated with hypoglycemia in CFRD. In
pilot studies, premeal treatment with ei-
therinsulinor1mgrepaglinideimproved
glucose and insulin excursion during a
standardized liquid mixed meal, but in-
sulin had a signiﬁcantly greater effect
(21). In the current study, the initial ben-
eﬁts of 2 mg repaglinide were not sus-
tained, because after 6 months the rate of
weight loss was similar to pretreatment
values and early gains were lost. There
was not a measurable change in medica-
tionadherencetoexplainthisresult.Con-
cernshavebeenraisedinotherconditions
of reduced 	-cell mass that agents that
stimulateinsulinsecretionmayultimately
wear out stressed 	-cells. In one study, a
year of insulin therapy improved endog-
enous insulin secretion in subjects with
early type 2 diabetes, whereas patients
who received 1 year of sulfonylurea ther-
apy had a decline in 	-cell function (22).
The proposed mechanism was “resting”
versus “exhausting” the cells. Prolonged
excessive stimulation with sulfonylureas
has been shown to induce 	-cell apopto-
sis in cultured human islets (23). Para-
doxically, repaglinide therapy had a
negative effect on weight in patients with
IGT. Thus, use of this agent in patients
withcysticﬁbrosisandIGTcannotberec-
ommended at present.
Insulin therapy is not easy. Although
the number of dropouts was similar
among treatment groups, patients receiv-
ing insulin injections were more likely to
choose to quit, whereas in the other
groupsdropoutwasmorelikelytobedue
toamedicalproblemthatdisqualiﬁedthe
patient from further study participation.
However, the majority of subjects in all
three groups completed the study, adher-
ence with study drug was similar among
theoralandinjectiontreatmentarms,and
therewasnodifferenceinCFQOLamong
treatment groups. During the study, pa-
tients were told that it was not known
whether diabetes therapy would have a
positivehealthimpact.Adherencemaybe
better when there is a proven beneﬁt.
Is premeal rapid-acting insulin the
best regimen for patients with CFRD
FH? It was chosen for this trial on the
basisofevidencethatmetabolicdefectsin
cysticﬁbrosisaremostpronouncedinthe
postprandialstate(4,5,23)andbecauseof
theoretical concerns that bedtime NPH
insulin might result in hypoglycemia in
thesepatientswithnormalfastingglucose
levels. At the time the study began, the
newer basal insulin analogs were not yet
widely available. Recently, small pilot
studies have suggested that low-dose in-
sulinglarginemayimproveweightorpul-
monary function in patients with cystic
ﬁbrosiswhohaveabnormalglucosetoler-
ancewithoutcausingsigniﬁcanthypogly-
cemia (19,20). Further work needs to be
done to compare and/or combine basal
and premeal insulin regimens in this
population.
No apparent clinical improvement
was seen with treatment of patients with
cystic ﬁbrosis who had severe IGT, al-
though for reasons that are not clear, BMI
improved in placebo-treated patients.
These data need to be interpreted with
caution. Glucose tolerance abnormalities
in cystic ﬁbrosis represent a spectrum.
We originally believed that subjects with
IGT and CFRD FH were metabolically
similar enough that their results could be
pooled, but their responses to treatment
proved to be different. There was greater
variability in the IGT group compared
with the CFRD FH group, along with
fewerparticipants;wewouldhaveneeded
a greater number of subjects with IGT to
derive any deﬁnitive conclusions about
the effect of treatment. Furthermore,
there were signiﬁcantly more men in the
IGTgroup.Thisdifferencemaybeimpor-
tantbecauseprognosisisworseinwomen
with CFRD (24). The present data dem-
onstrate that studies exploring carbohy-
drate metabolism in cystic ﬁbrosis should
consider subjects with CFRD separately
from those with IGT and that further re-
search is needed to determine the most
appropriate treatment of IGT.
In the CFRDT trial, insulin therapy
safely reversed chronic weight loss in pa-
tients with CFRD FH. Insulin may be
successfulinbreakingthecycleofprotein
catabolism, weight loss, and pulmonary
function decline because of its anabolic
effects. A signiﬁcant percentage of the
adult cystic ﬁbrosis patient population
could beneﬁt from this therapy, with a
substantial impact on morbidity and
mortality.
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